Immune Checkpoint Inhibitors for Cancer Therapy: Status and Future Directions
1, 2, 1
- 1Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, SAUDI ARABIA.
- 2Clinical Department, DataRevive USA LLC, Rockville, Maryland, UNITED STATES.
CORRESPONDENCE
Asim Najmi
Department of Pharmaceutical Chemistry and Pharmacognosy, College of Pharmacy, Jazan University, Jazan, SAUDI ARABIA.
Received: 17-02-2024; Accepted: 02-10-2024.
Volume 58, Issue 4s (Supplement) · pp. s1169-s1184 · 2024 · DOI: 10.5530/ijper.58.4s.115
ABSTRACT
Among various treatment modalities available for the treatment of cancer, immunotherapy is one of the important strategies used for the management of different malignancies. Immune checkpoint inhibitors are used for the treatment of cancers based on immunotherapy. Immune checkpoints are implicated when the proteins on the immune cells identify and bind to the ligand on the surface of other cells. These proteins are referred as immune checkpoint proteins. As soon as the checkpoint protein and ligand combine, they convey an “off” signal to the immune cells and prevent the immune system from killing the cancerous cells. Thus, immunotherapy drugs such as immune checkpoint inhibitors act by inhibiting the checkpoint protein molecules. This act stops the “off” signal, permitting the immune cells to destroy the cancerous cells. Programmed Death Ligand-1 (PD-L1) and Programmed Death-1 (PD-1) inhibitors have achieved clinical success with good overall survival rates in solid tumors. Considering remarkable outcomes in clinical investigations, various PD-L1 and PD-1 inhibitors have gained significant attention as onco-immunotherapeutic agents to treat various malignancies effectively. The present review aimed to explain the fundamentals of cancer immunotherapy, basics of checkpoints, inhibitors implicated in immune checkpoints, chemistry, clinical status, adverse events, resistance to checkpoint inhibitors and future scope.
KEYWORDS
REFERENCES
As publishedShowing references and in-text citations exactly as published.
Cite this article
SELECT FORMAT
Alam, M. S., Wang, S., & Najmi, A. (2024). Immune Checkpoint Inhibitors for Cancer Therapy: Status and Future Directions. Indian Journal of Pharmaceutical Education and Research, 58(4s), s1169-s1184. https://doi.org/10.5530/ijper.58.4s.115
Copyright and licence
© 2024 Author(s)
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited. CC BY 4.0